Acute Lymphoblastic Leukemia in a Patient With Advanced Breast Cancer Treated With Cyclin-Dependent Kinase 4/6...

Area of Science:

• Oncology
• Hematology

Background:

• Concurrent management of breast cancer and hematologic malignancies presents unique challenges.
• Treatment of invasive ductal carcinoma (IDC) in post-menopausal women often involves endocrine therapy and CDK 4/6 inhibitors.
• Philadelphia chromosome-positive B cell acute lymphoblastic leukemia (B-ALL) requires specific chemotherapeutic regimens.

Observation:

• A patient with IDC developed Philadelphia chromosome-positive B-ALL while on CDK 4/6 inhibitor and aromatase inhibitor (AI) therapy.
• The patient was treated with hyperfractionated cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, methotrexate, and cytarabine (hyperCVAD) plus dexamethasone for B-ALL.
• The combination of hyperCVAD with CDK 4/6 inhibitor + AI was administered.

Findings:

• The combined treatment regimen was well-tolerated, with only a single interruption of CDK 4/6 inhibitor and AI due to adverse effect intolerance.
• The patient achieved remission and remained on a CDK 4/6 inhibitor and ponatinib with manageable low-grade fatigue.
• The concurrent treatment approach demonstrated efficacy in managing both breast and hematologic malignancies.

Implications:

• This case highlights the feasibility and tolerability of combined treatment strategies for synchronous breast and hematologic cancers.
• Vigilant follow-up and integrated care are crucial for patients with multiple malignancies to ensure effective disease surveillance and management.
• Concurrent treatment can be an effective option, underscoring the importance of a multidisciplinary approach in complex oncologic cases.